Compare ASE Technology Holding Co Ltd (ASX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASE Technology Holding Co Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? ASE Technology Holding Co Ltd trades at $39.26 (market cap $85.75B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: ASE Technology Holding Co Ltd pays a 1.08% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ASE Technology Holding Co Ltd nearer its low. Which is the better fit depends on your goals.
| ASX | XBI | |
|---|---|---|
Market Cap | $85.75B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $45.12 | $164.28 |
52-Week Low | $9.63 | $86.92 |
Enterprise Value | $90.15B | — |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $39.56, up 5.23% today, showing strong momentum with three consecutive earnings beats. The stock maintains bullish technical signals with support at $38 and resistance at $40. Recent Q2 2026 results demonstrated robust growth in AI-driven semiconductor packaging demand, with the company increasing 2026 capital expenditure to $10.5 billion to expand capacity.
Outlook remains positive with 80% analyst buy ratings and projected revenue growth to $711.2 billion in 2026. Key risks include high valuation multiples (P/E 47.78) and significant capital investment requirements. The AI semiconductor boom provides substantial growth opportunity, though execution on expansion plans will be critical for sustained performance.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASE Technology Holding Co Ltd
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
